Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta.
Latest news
-
Precision BioSciences to raise $100m for off the shelf CAR-Ts
This is Precision’s first clinical-stage candidate, but it targets a familiar protein – CD19, which is also the focus of already approved CAR-Ts Novartis’ Kymriah and Gilead’s Yescarta.
-
NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access
Some recent examples seen as a success on both sides are deals to bring the groundbreaking CAR-T drugs to patients – Gilead’s Yescarta and Novartis’ Kymriah gaining access in England
-
CMS proposes coverage scheme for CAR-T therapies
Sciences’ Yescarta (axicabtagene ciloleucel) given the nod shortly afterwards for various forms of non-Hodgkin’s lymphoma (NHL) including DLBCL. ... Yescarta meanwhile brought in $264m in 2018, but slowed in the fourth-quarter with its $81m tally
-
Gilead awaits CEO and readouts to revive fortunes
This is thanks to its HIV franchise, which grew 16% over the year to $14.6bn, hopes of faster growth from its CAR-T pioneer Yescarta, plus a handful of ... As the HIV franchise will face generics in the US and Europe this year, and its hepatitis C
-
CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL
with its rival, Gilead's Yescarta, in the key DLBCL market. ... The company confirmed that the CAR-T therapy only achieved $76m in revenues in 2018, far behind the $183m Yescarta earned in the first nine months of last year.
More from news
Approximately 7 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Cell and gene therapy
Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene
-
New models of NHS care – new models of pharma response?
Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
therapies, such as CAR-Ts Kymriah and Yescarta.
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June ... Kymriah and Yescarta might
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Scientific Director – Medical Communications
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Senior Medical Writer
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Health Consultant - Brand Comms
-
Competitive Salary
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Manager, Medical Communications, London
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
Subscribe to our email news alerts
PMHub
Clark Health Communications
Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
